Author of

• 11358

  +

  MO11 - Screening and Epidemiology (ID 131)

  • Event: WCLC 2013
  • Type: Mini Oral Abstract Session
  • Track: Imaging, Staging & Screening
  • Presentations: 1
  • Moderators:P. Zimmerman, J. Bowden
  • Coordinates: 10/28/2013, 16:15 - 17:45, Bayside 201 - 203, Level 2

  • 11360

    +

    MO11.02 - Validation of electronic nose exhaled breath VOC profile in discriminating between subjects with early stage lung cancer and healthy ever smokers. (ID 2574)

    16:15 - 17:45  |  Author(s): A.G. Dent
    • Abstract
    • Presentation
    • Slides

    Background
    Early diagnosis of lung cancer is associated with a better survival. The measurement of volatile organic compounds (VOCs) in exhaled breath using an electronic nose may prove to be a novel, effective and simple technique for screening and diagnosing lung cancer. The aim was to test the validity of the VOC profile in discriminating subjects with early stage lung cancer (I and II) (ESLC) from healthy ever smokers (HS).

    Methods
    243 subjects: 54 ESLC and 189 HS provided a breath sample after tidally breathing through an inspiratory port filter for 5 minutes. It was analysed using a 32 sensor Cyranose 320 (Smiths Detection). Subjects were divided into training (n=159) and independent test set (n=84) groups. Canonical discrimination analyses were performed to determine significance of difference between subject groups and calculate cross validated accuracy (CVV) of the groups using leave one out classification method. Area under the curve (AUC) of Receiver Operating Characteristic Curves were also determined (SPSS V17.0).

    Results
    Validation of the training VOC profile model using an independent test group showed 79% accuracy (p=0.001) in distinguishing ESLC (n=20) from HS (n=64). (AUC 0.933). There was no significant difference in age, lung function and smoking history between the training and test groups.

    Conclusion
    Exhaled breath VOC profile model to discriminate between ESLC subjects and HS was validated in an independent group with a high accuracy. A clinically high sensitivity of the VOC profile model to discriminate between ESLC and HS can be achieved by selecting an appropriate cut point. The cyranose has potential to be a clinically useful diagnostic and screening tool for early stage lung cancer.

    Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.